<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6142">
  <stage>Registered</stage>
  <submitdate>14/06/2016</submitdate>
  <approvaldate>14/06/2016</approvaldate>
  <nctid>NCT02802345</nctid>
  <trial_identification>
    <studytitle>Efficacy and Safety of Nintedanib When Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment</studytitle>
    <scientifictitle>INSTAGE: A 24-week, Double-blind, Randomized, Parallel-group Study Evaluating the Efficacy and Safety of Oral Nintedanib Co-administered With Oral Sildenafil, Compared to Treatment With Nintedanib Alone, in Patients With Idiopathic Pulmonary Fibrosis (IPF) and Advanced Lung Function Impairment</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2015-002619-14</secondaryid>
    <secondaryid>1199.36</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Idiopathic Pulmonary Fibrosis</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Connective tissue diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Nintedanib
Treatment: drugs - Placebo
Treatment: drugs - Sildenafil

Experimental: Nintedanib + placebo matching sildenafil - 

Active Comparator: Nintedanib + Sildenafil - 


Treatment: drugs: Nintedanib


Treatment: drugs: Placebo


Treatment: drugs: Sildenafil


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>change from baseline in St George's Respiratory Questionnaire (SGRQ) total score at week 12</outcome>
      <timepoint>week 12</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>change from baseline in SGRQ total score at week 24</outcome>
      <timepoint>week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>change from baseline in UCSD SOBQ at week 24</outcome>
      <timepoint>week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of patients with on-treatment Serious Adverse Events (SAE) from baseline to week 24</outcome>
      <timepoint>week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>change from baseline in dyspnea using the University of California San Diego Shortness of Breath Questionnaire (UCSD SOBQ) at week 12</outcome>
      <timepoint>week 12</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria:

          -  Written informed consent consistent with International Conference on
             Harmonization-Good Clinical Practice and local laws, signed prior to any study
             procedures being performed (including any required washout);

          -  Male or female patients aged &gt;= 40 years at visit 1;

          -  A clinical diagnosis of IPF within the last 6 years before visit 1, based upon the
             American Thoracic Society/European Respiratory Society/Japanese Respiratory
             Society/Latin American thoracic Association 2011 guideline [P11-07084];

          -  Combination of high-resolution computed tomography (HRCT) pattern, and if available,
             surgical lung biopsy pattern consistent with a diagnosis of IPF as assessed by the
             investigator based on a HRCT scan performed within 18 months of visit 1;

          -  Carbon Monoxide Diffusion Capacity (corrected for Hb) less or equal to 35% predicted
             of normal at visit 1.</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

          -  Previous enrolment in this trial;

          -  Alanine Transaminase, Aspartate Transaminase &gt; 1.5 fold upper limit of normal (ULN) at
             visit 1;

          -  Total bilirubin &gt; 1.5 fold ULN at visit 1;

          -  Relevant airways obstruction (i.e. pre-bronchodilator Forced Expiratory Volume in 1
             second/Forced Vital Capacity &lt;0.7 at visit 1)

          -  History of myocardial infarction within 6 months of visit 1 or unstable angina within
             1 month of visit 1

          -  Bleeding Risk:

               -  Known genetic predisposition to bleeding;

               -  Patients who require fibrinolysis, full-dose therapeutic anticoagulation (e.g.
                  vitamin K antagonists, direct thrombin inhibitors, heparin, hirudin, etc.) or
                  high dose antiplatelet therapy;

               -  History of haemorrhagic central nervous system (CNS) event within 12 months prior
                  to visit 1;

               -  History of haemoptysis or haematuria, active gastro-intestinal bleeding or ulcers
                  and/or major injury or surgery within 3 months prior to visit 1;

               -  International normalised ratio (INR) &gt; 2 at visit 1;

               -  Prothrombin time (PT) and activated partial thromboplastin time (aPTT) &gt; 150% of
                  institutional ULN at visit 1;

          -  Planned major surgery during the trial participation, including lung transplantation,
             major abdominal or major intestinal surgery;

          -  History of thrombotic event (including stroke and transient ischemic attack) within 12
             months of visit 1;

          -  Creatinine clearance &lt; 30 mL/min calculated by Cockcroft-Gault formula at visit 1;

          -  Presence of aortic stenosis (AS) per investigator judgement at visit 1;

          -  Severe chronic heart failure: defined by left ventricular ejection fraction (EF) &lt; 25%
             per investigator judgement at visit 1;

          -  Presence of idiopathic hypertrophic subaortic stenosis (IHSS) per investigator
             judgement at visit 1;

          -  Second-degree or third-degree atrioventricular (AV) block on electrocardiogram (ECG)
             per investigator judgement at visit 1;

          -  Hypotension (systolic blood pressure [SBP] &lt; 100 mm Hg or diastolic blood pressure
             [DBP] &lt; 50 mm Hg) (symptomatic orthostatic hypotension) at visit 1;

          -  Uncontrolled systemic hypertension (SBP &gt; 180 mmHg; or DBP &gt; 100 mmHg) at visit 1;

          -  Known penile deformities or conditions (e.g., sickle cell anemia, multiple myeloma,
             leukemia) that may predispose to priapism;

          -  Retinitis pigmentosa;

          -  History of vision loss;

          -  History of nonarteritic ischemic optic neuropathy;

          -  Veno-occlusive disease;

          -  History of acute IPF exacerbation or respiratory infection within 8 weeks of visit 2.

          -  Treatment with nitrates, n-acetylcysteine, pirfenidone, azathioprine,
             cyclophosphamide, cyclosporine, prednisone &gt;15 mg daily or &gt;30 mg every 2 days OR
             equivalent dose of other oral corticosteroids as well as any investigational drug
             within 4 weeks of visit 2;

          -  Treatment with prostaglandins (e.g., epoprostenol, treprostinil), endothelin-1
             antagonists (e.g., bosentan, sitaxsentan, ambrisentan), phosphodiesterase inhibitors
             (e.g., sildenafil, tadalafil, vardenafil) or a stimulator of guanylatcyclase
             (e.g.,riociguat) within 4 weeks of visit 2;

          -  Treatment with potent cytochrome CYP3A4 inhibitors such as ketoconazole, itraconazole
             and ritonavir within 4 weeks of visit 2;

          -  Supplementation with L-arginine and concurrent use of grapefruit juice or St John's
             wort within 4 weeks of visit 2;

          -  Treatment with the reduced dose of nintedanib (100 mg bid) within 4 weeks of visit 2;
             27. Permanent discontinuation of nintedanib in the past due to adverse events
             considered drug-related;

          -  Known hypersensitivity or intolerance to nintedanib, sildenafil, galactose, peanut or
             soya or any other components of the study medication;

          -  A disease or condition which in the opinion of the investigator may interfere with
             testing procedures or put the patient at risk when participating in this trial;

          -  Alcohol or drug abuse which in the opinion of the treating physician would interfere
             with treatment;

          -  Further exclusion criteria apply.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional(has expanded access)</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>30/06/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>250</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>15/03/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>Royal Prince Alfred Hospital - Camperdown, Sydney</hospital>
    <hospital>Concord General Repatriation Hospital -Ambulatory Care Unit - Concord</hospital>
    <hospital>The Alfred Hospital- Respiratory Medicine - Melbourne</hospital>
    <postcode>2050 - Camperdown, Sydney</postcode>
    <postcode>2139 - Concord</postcode>
    <postcode>3004 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Antwerpen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Yvoir</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rennes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Coswig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Donaustauf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg im Breisgau</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Gießen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Greifswald</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hannover</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Immenhausen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Solingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Ahmedabad</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Coimbatore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Kolkata</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Pune</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Chieti Scalo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>FORLì</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Modena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Padova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Torrette di Ancona (Ancona)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Aichi, Seto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Fukuoka, Kurume</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Gifu, Ogaki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Ibaraki, Naka-gun</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kanagawa, Yokohama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo, Bunkyo-ku</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo, Ota-ku</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Guadalajara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Monterrey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>México</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Girona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Pozuelo de Alarcón</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cambridge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Dundee, Scotland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Sheffield</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Tyne and Wear</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Boehringer Ingelheim</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To assess efficacy and safety of concomitant treatment with nintedanib and sildenafil in
      Idiopathic Pulmonary Fibrosis (IPF) patients with advanced lung function impairment.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02802345</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Boehringer Ingelheim</name>
      <address>Boehringer Ingelheim</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Boehringer Ingelheim Call Center</name>
      <address />
      <phone>1-800-243-0127</phone>
      <fax />
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>